ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

HCM Hutchmed (china) Limited

297.50
-6.50 (-2.14%)
30 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hutchmed (china) Limited LSE:HCM London Ordinary Share KYG4672N1198 ORD USD0.10
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -6.50 -2.14% 297.50 296.00 299.00 309.00 298.00 306.00 123,751 16:35:10
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 838M 100.78M - N/A 0
Hutchmed (china) Limited is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchmed (china) was 304p. Over the last year, Hutchmed (china) shares have traded in a share price range of 173.60p to 338.00p.

Hutchmed (china) currently has 871,256,270 shares in issue.

Hutchmed (china) Share Discussion Threads

Showing 4051 to 4073 of 4100 messages
Chat Pages: 164  163  162  161  160  159  158  157  156  155  154  153  Older
DateSubjectAuthorDiscuss
03/2/2024
07:36
thankyou 1jat, I do think that I will be buying at some stage, possibly later this year if or when the geo-politics issues subside. This is such a great under valued Company. My specific issue is one of oppoertunity cost here and my problem of effectively dead money and I have a specific timeframe to grow my investment and frankly time will run out!
nerdofsteel
03/2/2024
00:47
More positive news yesterday and no positive impact on the share price. HCM really are in a rut at the moment. Thought 2024 was going to be better, but still 11 months to go.
lauders
02/2/2024
21:06
NoS
I for one will continue to value your thoughts…..as a long term follower of HCM I expect you will keep an eye on it, in case there is a change of tone and fortune - I also expect you will buy back in at some point…

Good luck with your new investments….tell us what you select.

1jat
02/2/2024
13:19
Bareknee - Bitter posts just make it look like you're continually trying to validate your reasons for selling.

Not at all, I was stating the facts as I see them..

nerdofsteel
01/2/2024
17:38
Let it go DaveyNerd. For better or worse you've sold up.

Bitter posts just make it look like you're continually trying to validate your reasons for selling. It's like the reverse of the Quindell situation was for you.

Live, learn and move on, but don't give up the day job !

bareknee
01/2/2024
09:08
Agree Lauders; to not engage with shareholders and do absolutely nothing given the recent decline, does just smack of apathy, and comes across as a little feeble.
mcmather
01/2/2024
08:37
It has been stated they don't really "care" about their shareholders mcmather. I suppose your point sort of confirms this, unfortunately.
lauders
01/2/2024
08:31
Shame there wasn't an update of sorts:

"HUTCHMED (China) Limited (“HUTCHMEDR21;) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2023 on Wednesday, February 28, 2024 at 6:30 am Eastern Standard Time (EST) / 11:30 am Greenwich Mean Time (GMT) / 7:30 pm Hong Kong Time (HKT)."

mcmather
31/1/2024
22:38
Bleak viewing the decline over the last 12 months
mcmather
30/1/2024
15:39
and the share price falls again as usual
nerdofsteel
30/1/2024
09:28
Bit more coverage just landed (nothing really more) here:

“Hutchmed celebrates cancer drug approval in hometown of Hong Kong”


And a bit of coverage from last week (23 Jan 2024): “Patients with previously treated metastatic colorectal cancer (CRC) experienced significant improvement in quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) when treated with a combination of Fruzaqla (fruquintinib) with best supportive care when compared with treatment via placebo and best supportive care, according to post hoc analysis findings from the phase 3 FRESCO-2 trial presented at the 2024 Gastrointestinal Cancers Symposium.”

mcmather
30/1/2024
07:23
Closed down 0.25% so the news managed to claw back some of the earlier losses.
lauders
30/1/2024
05:03
Some good news from HCM today.

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, January 30, 2024: HUTCHMED (China) Limited (Nasdaq/AIM:​HCM, HKEX:​13) (“HUTCHMEDR21;) today announces that the marketing approval of ELUNATEĀ® (fruquintinib) by the Pharmacy and Poisons Board of Hong Kong for the treatment of adult patients with previously treated metastatic colorectal cancer (“CRC”). ELUNATEĀ® is a selective oral inhibitor of vascular endothelial growth factor (“VEGF”) receptors -1, -2 and -3, which play a pivotal role in blocking tumor angiogenesis.

Will it be enough to make the share price + for once? Currently DOWN in HK by 1.88%!

lauders
29/1/2024
14:46
"But hcm still irritates you"

not really, I was just posting an observation about geo-politics at play here and yes I have sold, but I may well buy back in if things begin to improve. In the meantime I've made a packet on Nvidia, more in a month than I have being invested in HCM over 7 years...

nerdofsteel
28/1/2024
18:23
Lauders - I agree with your sentiment but it could be some time in coming… the macro environment is again at play - I read a US congressman has tabled a bill to sanction certain Chinese Biopharma due to links to the China Army….which cannot be helping US investors.

I doubt many investors in smaller pharma are actually expecting/wanting them to transition into self supporting larger pharma cos.

It is not clear what CKHH position is….they seem to be happy to hold and see the company grow - they dont currently need any cash from their stake, this effectively means HCM is not for sale. If the Vodafone/3 deal goes through CKHH will pocket a couple of Billion and have options to sell out in 2-3 years….

I expect there will be M&A within China biopharma soon…..many companies have cash for a couple of years if fund raising becomes more difficult they will have to be sold…HCM may get to self sustainability before this happens which will put them into a stronger position to buy.

1jat
27/1/2024
01:52
One thing is for sure. Anyone with funds to invest at these low RSI levels will make some money going forward. Can't stay at these levels forever, surely? Just needs some good news on trials, M&A activity, sales and a rebound should materialize. Down over 20% this year alone!
lauders
26/1/2024
12:33
NoS I thought you were out? Really this time. But hcm still irritates you. Why? Move on.
shaker45
26/1/2024
11:36
just think, HK investors who took shares at the IPO have lost two thirds of their money

China is now effectively uninvestible and the Chinese Communist Party knows it. The property sector is collapsing and everything else will follow.

nerdofsteel
24/1/2024
08:02
The Company seems to be quite inept when it comes to Investors, particularly individual ones. I have asked many important questions at the AGM and Simon To has always treated me with disdain. They also need to update their pipeline, it's 6 months out of date.
nerdofsteel
23/1/2024
16:35
Agree, it does make a difference especially if read out at a board meeting, could just be enough to sway opinion.

Posted a few more ideas on other board if you have access.


Lauders22 Jan '24 - 08:58 - 3988 of 3991

1pencil
22/1/2024
22:45
US closed -7.50%. Will we see any response from the company?

There appeared to be support on the US weekly at 14.48ish. Hmmmm.

FWIW: "The 55 rating InvestorsObserver gives to HUTCHMED (China) Ltd (HCM) stock puts it near the top of the Drug Manufacturers - Specialty & Generic industry. In addition to scoring higher than 80 percent of stocks in the Drug Manufacturers - Specialty & Generic industry, HCM’s 55 overall rating means the stock scores better than 55 percent of all stocks...Over the past year the S&P 500 has risen 20.68% while HCM has fallen -26.98%"

mcmather
22/1/2024
11:28
Good point. What is to stop the majority shareholder making a cheap bid for the remaining shares, although it would need to get > 75%.
tday
22/1/2024
10:42
At this rate Hutchison will buy it back themselves .

It would be a great deal for them!

dbadvn
Chat Pages: 164  163  162  161  160  159  158  157  156  155  154  153  Older

Your Recent History

Delayed Upgrade Clock